These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8279780)

  • 1. Cancer therapy using radioimmunoconjugates. Implications for breast cancer.
    Tempero M; Colcher D; Dalrymple G; Harrison K; Holdeman K; Joshi S; Quadri S; Linder J; Augustine S; Reed E
    Ann N Y Acad Sci; 1993 Nov; 698():406-17. PubMed ID: 8279780
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
    Press OW; Shan D; Howell-Clark J; Eary J; Appelbaum FR; Matthews D; King DJ; Haines AM; Hamann P; Hinman L; Shochat D; Bernstein ID
    Cancer Res; 1996 May; 56(9):2123-9. PubMed ID: 8616860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
    Denardo SJ; O'Grady LF; Richman CM; Goldstein DS; O'Donnell RT; Denardo DA; Kroger LA; Lamborn KR; Hellström KE; Hellström I; Denardo GL
    Anticancer Res; 1997; 17(3B):1745-51. PubMed ID: 9179228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magic bullets pursue recurrent breast cancer.
    Jones-Bey H
    Diagn Imaging (San Franc); 1992 Sep; 14(9):97, 103-8, 113. PubMed ID: 10147892
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of trastuzumab.
    Vogel CL; Reddy JC; Reyno LM
    Cancer Res; 2005 Mar; 65(5):2044. PubMed ID: 15753405
    [No Abstract]   [Full Text] [Related]  

  • 6. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods.
    Smellie WJ; Dean CJ; Sacks NP; Zalutsky MR; Garg PK; Carnochan P; Eccles SA
    Cancer Res; 1995 Dec; 55(23 Suppl):5842s-5846s. PubMed ID: 7493357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas.
    Peterson JA; Blank EW; Ceriani RL
    Cancer Res; 1997 Mar; 57(6):1103-8. PubMed ID: 9067279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
    Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
    Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
    Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer.
    Peterson JA; Couto JR; Taylor MR; Ceriani RL
    Cancer Res; 1995 Dec; 55(23 Suppl):5847s-5851s. PubMed ID: 7493358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
    Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
    Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.
    Stipsanelli E; Valsamaki P
    Hell J Nucl Med; 2005; 8(2):103-8. PubMed ID: 16142251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms.
    Ceriani RL; Blank EW; Couto JR; Peterson JA
    Cancer Res; 1995 Dec; 55(23 Suppl):5852s-5856s. PubMed ID: 7493359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications.
    Wahl RL
    J Nucl Med; 1998 Aug; 39(8 Suppl):1S. PubMed ID: 9708563
    [No Abstract]   [Full Text] [Related]  

  • 20. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
    DeNardo DA; DeNardo GL; Yuan A; Shen S; DeNardo SJ; Macey DJ; Lamborn KR; Mahe M; Groch MW; Erwin WD
    J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.